Common use
Vfend is a broad-spectrum triazole antifungal medication containing voriconazole as its active ingredient, prescribed for the treatment of serious, invasive, and potentially life-threatening fungal infections that pose grave risks to vulnerable patient populations. When you buy Vfend online, you are getting access to a powerful and clinically essential antifungal treatment that is considered first-line therapy by infectious disease specialists worldwide for the most dangerous systemic fungal infections. This antifungal medication carries primary indications for invasive aspergillosis (the most common and frequently fatal mold infection in immunocompromised patients), candidemia and disseminated candidiasis in non-neutropenic patients (bloodstream infections caused by Candida species that can seed multiple organs), esophageal candidiasis (a painful fungal infection of the esophageal lining common in AIDS patients), and serious deep-tissue infections caused by less common but highly aggressive molds including Scedosporium apiospermum and Fusarium species, which are notoriously difficult to treat and often resistant to other antifungal agents. Voriconazole works by selectively and potently inhibiting the fungal cytochrome P450 enzyme CYP51, also known as 14-alpha-demethylase, which catalyzes a critical step in the biosynthesis of ergosterol — the principal sterol component of fungal cell membranes that is analogous to cholesterol in human cell membranes. Without adequate ergosterol production, the fungal cell membrane loses its structural integrity, becomes abnormally permeable, and ultimately can no longer maintain the electrochemical gradients necessary for cell survival, effectively stopping fungal growth (fungistatic activity at lower concentrations) and killing the organism (fungicidal activity at higher concentrations against susceptible species). As a Vfend generic equivalent, this medication provides the same pharmaceutical-grade triazole antifungal formula that is trusted by infectious disease specialists, hematologists, oncologists, and transplant physicians worldwide, particularly for treating immunocompromised patients — including those undergoing chemotherapy for hematological malignancies, bone marrow or solid organ transplant recipients, and HIV/AIDS patients — who are most vulnerable to these dangerous and often fatal invasive fungal infections.

Dosage and direction
Take Vfend orally or via intravenous (IV) infusion exactly as prescribed by your infectious disease specialist, hematologist, or transplant physician, typically administered every 12 hours (twice daily). Treatment almost always begins with a loading dose on day one to rapidly achieve therapeutic drug levels: 6 mg/kg IV every 12 hours for two doses, or 400 mg orally every 12 hours for two doses (for patients weighing 40 kg or more). This is followed by a lower maintenance dose starting on day two: 4 mg/kg IV every 12 hours, or 200 mg orally every 12 hours for patients 40 kg or above (100 mg every 12 hours for patients under 40 kg). Oral tablets should be taken on an empty stomach — at least one hour before or at least one hour after meals — for optimal gastrointestinal absorption of this antifungal medication, as food significantly reduces the bioavailability and peak plasma levels of voriconazole. Swallow the tablets whole with a full glass of water; do not crush, chew, or dissolve them. If using the oral suspension formulation, shake the bottle thoroughly for at least 10 seconds before each dose and use the measuring device provided. The duration of treatment with voriconazole depends on the type, severity, and anatomical location of the invasive fungal infection, your clinical and radiological response to treatment, your underlying immune status, and whether the immunosuppressive condition is reversible (e.g., recovery from neutropenia after chemotherapy). Treatment typically continues for a minimum of 6 to 12 weeks for invasive aspergillosis, but may be significantly longer — months to years in some cases — for patients with ongoing immunosuppression. Do not stop taking this triazole antifungal prematurely, even if you feel significantly better and your symptoms have resolved, as incomplete treatment courses frequently lead to treatment failure, relapse of the fungal infection, and the potential development of antifungal resistance, which would severely limit future treatment options for a potentially fatal infection.

Precautions
Before you buy voriconazole, have a comprehensive discussion with your doctor about your complete medical history, current medications, and co-existing conditions. This is particularly important if you have liver disease or hepatic impairment (since voriconazole is extensively metabolized by the liver and can itself cause hepatotoxicity), kidney impairment (especially important if considering the IV formulation, which contains the solubilizing agent sulfobutylether-beta-cyclodextrin that accumulates in renal insufficiency), heart rhythm problems including QT prolongation, a personal or family history of long QT syndrome, sudden cardiac death, or arrhythmias, electrolyte abnormalities (particularly hypokalemia or hypomagnesemia, which predispose to QT prolongation), or any pre-existing vision issues. Regular and frequent liver function testing (ALT, AST, bilirubin, alkaline phosphatase) is essential during the entire course of treatment, as voriconazole can cause clinically significant hepatotoxicity ranging from mild enzyme elevations to severe hepatitis, cholestasis, fulminant liver failure, and death. Liver function tests should be obtained at baseline, within the first week, then at least monthly during treatment, and whenever signs or symptoms of hepatic dysfunction appear (nausea, vomiting, right upper abdominal pain, jaundice, dark urine). Visual function monitoring should also be conducted, particularly during the first weeks of therapy, as visual disturbances are among the most common side effects of voriconazole and are reported by up to 30% of patients. These may include altered or enhanced visual perception, blurred vision, changes in color vision (chromatopsia), photophobia (light sensitivity), and visual hallucinations. Patients should avoid driving at night, operating heavy machinery, or engaging in hazardous activities if visual disturbances occur, as these can significantly impair visual function, particularly in low-light conditions. Protect your skin rigorously from direct sunlight and all forms of UV exposure (including tanning beds) during and after treatment, as voriconazole is associated with photosensitivity reactions (severe sunburn with minimal sun exposure), phototoxicity, and with prolonged use (months to years), a well-documented and significantly increased risk of cutaneous malignancy, particularly squamous cell carcinoma and melanoma. Patients on long-term voriconazole therapy should have regular dermatological skin examinations. Immunocompromised patients should have their voriconazole blood levels monitored through therapeutic drug monitoring (TDM) to ensure that plasma concentrations remain within the therapeutic window — target trough levels are generally 1 to 5.5 mcg/mL. Subtherapeutic levels are associated with treatment failure and increased mortality, while supratherapeutic levels are associated with increased toxicity, particularly hepatotoxicity and neurotoxicity.

Contraindications
Do not use Vfend if you are allergic to voriconazole or any other azole antifungal agents (including fluconazole, itraconazole, posaconazole, or isavuconazole). This triazole antifungal is strictly contraindicated for concurrent use with several medications due to potentially dangerous and life-threatening pharmacokinetic interactions: Rifampin and carbamazepine are potent CYP450 inducers that reduce voriconazole plasma levels by up to 96% and 70% respectively, rendering the antifungal completely ineffective and essentially leaving the patient unprotected against their invasive fungal infection. Rifabutin at standard doses, long-acting barbiturates (phenobarbital), ergot alkaloids (ergotamine, dihydroergotamine — risk of ergotism), sirolimus (voriconazole increases sirolimus levels by up to 11-fold, causing serious toxicity), pimozide and quinidine (risk of fatal cardiac arrhythmias due to QT prolongation), and St. John's wort (potent CYP inducer) are all strictly contraindicated. The IV formulation of Vfend contains the solubilizing excipient sulfobutylether-beta-cyclodextrin (SBECD), which is renally eliminated and accumulates significantly in patients with moderate-to-severe renal impairment (creatinine clearance less than 50 mL/min). In these patients, the oral formulation of voriconazole should be used preferentially unless the severity of the infection mandates IV therapy, in which case the patient's renal function must be closely monitored.

Possible side effect
Common side effects of this antifungal medication include visual disturbances (reported in approximately 20-30% of patients and typically transient, lasting 30 to 60 minutes after dosing), skin rash and photosensitivity reactions, fever, nausea, vomiting, diarrhea, abdominal pain, headache, and elevated liver enzymes on blood tests. The visual side effects are among the most characteristic and recognizable effects of voriconazole therapy, and usually manifest as enhanced brightness or glare, blurred vision, altered color perception (objects may appear to have a yellow-green tinge), wavy lines in the visual field, or photophobia. These visual changes typically occur within the first 30 minutes after an oral dose and resolve spontaneously within 30 to 60 minutes. Serious but less common adverse effects that require immediate medical attention include significant hepatotoxicity (liver damage presenting with jaundice, elevated bilirubin, right upper quadrant pain, nausea, and potentially progressing to liver failure), severe and potentially life-threatening skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis — presenting with widespread blistering, skin peeling, mucosal erosions, and systemic illness), visual or auditory hallucinations (particularly at supratherapeutic drug levels), clinically significant QT prolongation with risk of torsades de pointes and sudden cardiac death, adrenal insufficiency, periostitis and skeletal pain with chronic use (fluoride-related bone toxicity), and peripheral neuropathy. Immunocompromised patients receiving long-term voriconazole therapy (particularly transplant recipients and patients with chronic granulomatous disease) should undergo regular and thorough dermatological skin examinations for early detection of cutaneous malignancies, particularly aggressive squamous cell carcinoma, which has been associated with chronic voriconazole phototoxicity and occurs at significantly higher rates in this population. Report any new, changing, or suspicious skin lesions to your healthcare provider promptly.

Drug interaction
Vfend has extensive, numerous, and clinically critical drug interactions due to its potent inhibitory and substrate effects on multiple cytochrome P450 enzymes, particularly CYP2C19, CYP2C9, and CYP3A4. Before you buy Vfend online or initiate voriconazole therapy, provide your doctor and pharmacist with a complete, comprehensive, and up-to-date list of every prescription medication, over-the-counter drug, herbal product, dietary supplement, and recreational substance you are taking or have recently taken. Voriconazole significantly and often dramatically increases the blood levels and pharmacological effects of many commonly used medications metabolized by CYP enzymes, frequently requiring substantial dose reductions to avoid toxicity. Key interactions include: tacrolimus (reduce dose by approximately two-thirds and monitor levels closely), cyclosporine (reduce dose by approximately half), sirolimus (contraindicated — 11-fold increase in exposure), warfarin (markedly prolonged INR — requires frequent INR monitoring and dose adjustment), HMG-CoA reductase inhibitors/statins (increased risk of rhabdomyolysis — reduce statin dose or use alternatives not metabolized by CYP3A4), benzodiazepines including midazolam and triazolam (prolonged and excessive sedation), calcium channel blockers, and opioids including methadone and fentanyl (risk of respiratory depression). Proton pump inhibitors (particularly omeprazole) can increase voriconazole levels and may require omeprazole dose reduction. Drugs that induce CYP450 enzymes (rifampin, phenytoin, efavirenz, long-acting barbiturates) can drastically reduce voriconazole plasma levels to subtherapeutic concentrations, leading to treatment failure. If phenytoin must be co-administered, the voriconazole maintenance dose must be doubled and phenytoin levels monitored closely. Therapeutic drug monitoring of voriconazole trough levels is strongly recommended when co-administering this triazole antifungal with any potentially interacting medication to ensure both efficacy and safety.

Missed dose
If you miss a dose of Vfend, take it as soon as you remember unless it is within approximately 4 hours of your next scheduled dose. In that case, skip the missed dose entirely and continue with your regular 12-hour dosing schedule — do not take a double dose to compensate for a missed one. Consistent and regular dosing is critically important for maintaining adequate therapeutic blood levels of this antifungal medication throughout the dosing interval to effectively combat invasive fungal infections, which can progress rapidly in immunocompromised patients. If you repeatedly miss doses or have difficulty adhering to the twice-daily schedule, notify your healthcare provider promptly, as subtherapeutic voriconazole levels are directly associated with treatment failure, disease progression, and increased mortality in patients with invasive aspergillosis and other serious fungal infections. Your doctor may consider therapeutic drug monitoring to verify that your blood levels remain within the effective range.

Overdose
Symptoms of voriconazole overdose may include severe visual disturbances (photophobia, hallucinations, altered visual perception), auditory hallucinations, severe nausea, profuse vomiting, diarrhea, significant liver dysfunction (evidenced by jaundice, markedly elevated liver enzymes, and coagulopathy), and potentially dangerous cardiac arrhythmias including QT prolongation and torsades de pointes. Neurological symptoms such as confusion, agitation, tremor, and altered mental status may also occur at toxic drug levels. There is no specific antidote for a Vfend overdose. Treatment is entirely supportive and symptomatic, and should be conducted in a hospital setting with continuous cardiac monitoring. Gastric lavage may be considered if performed shortly after oral ingestion (within 1-2 hours). Voriconazole is extensively metabolized by the liver, and hemodialysis may assist in removing the IV formulation's cyclodextrin vehicle (SBECD) but has limited efficacy in removing voriconazole itself due to its high protein binding (approximately 58%) and large volume of distribution. Seek immediate emergency medical attention if an overdose of this triazole antifungal is suspected.

Storage
Store Vfend tablets at controlled room temperature between 59°F and 86°F (15°C to 30°C), protected from light, excessive heat, and moisture. Keep this antifungal medication in its original container with the cap tightly closed, and store out of reach of children and pets at all times. Do not use expired medication — always check the expiration date on the packaging before each use, as the potency and stability of voriconazole cannot be guaranteed past the expiration date. The reconstituted powder for oral suspension should be stored at controlled room temperature (do not refrigerate) and discarded 14 days after reconstitution. The reconstituted IV solution should be used immediately after preparation or stored under refrigeration (2-8°C) for up to 24 hours, as directed by pharmacy guidelines. Dispose of any unused voriconazole tablets or solution properly through a medication take-back program or as directed by your pharmacist — do not flush down the toilet or drain unless specifically instructed.

Disclaimer

We provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information at the site cannot be used for self-treatment and self-diagnosis. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.